221 related articles for article (PubMed ID: 31323706)
21. Denser plasma clot formation and impaired fibrinolysis in paroxysmal and persistent atrial fibrillation while on sinus rhythm: association with thrombin generation, endothelial injury and platelet activation.
Drabik L; Wołkow P; Undas A
Thromb Res; 2015 Aug; 136(2):408-14. PubMed ID: 26048399
[TBL] [Abstract][Full Text] [Related]
22. Altered fibrin clot properties in advanced lung cancer: strong impact of cigarette smoking.
Ząbczyk M; Królczyk G; Czyżewicz G; Plens K; Prior S; Butenas S; Undas A
Med Oncol; 2019 Mar; 36(4):37. PubMed ID: 30891644
[TBL] [Abstract][Full Text] [Related]
23. Altered plasma fibrin clot properties in patients with digestive tract cancers: links with the increased thrombin generation.
Gronostaj K; Richter P; Nowak W; Undas A
Thromb Res; 2013 Mar; 131(3):262-7. PubMed ID: 23273404
[TBL] [Abstract][Full Text] [Related]
24. Altered plasma fibrin clot properties and fibrinolysis in patients with multiple myeloma.
Undas A; Zubkiewicz-Usnarska L; Helbig G; Woszczyk D; Kozińska J; Dmoszyńska A; Podolak-Dawidziak M; Kuliczkowski K
Eur J Clin Invest; 2014 Jun; 44(6):557-66. PubMed ID: 24738991
[TBL] [Abstract][Full Text] [Related]
25. Recurrent venous thromboembolism patients form clots with lower elastic modulus than those formed by patients with non-recurrent disease.
Baker SR; Zabczyk M; Macrae FL; Duval C; Undas A; Ariëns RAS
J Thromb Haemost; 2019 Apr; 17(4):618-626. PubMed ID: 30725502
[TBL] [Abstract][Full Text] [Related]
26. Therapy with high-dose statins reduces soluble P-selectin: The impact on plasma fibrin clot properties.
Siudut J; Pudło J; Konieczyńska M; Polak M; Jawień J; Undas A
Int J Cardiol; 2023 Feb; 373():110-117. PubMed ID: 36410546
[TBL] [Abstract][Full Text] [Related]
27. Elevated factor XIa as a modulator of plasma fibrin clot properties in coronary artery disease.
Paszek E; Malinowski KP; Ząbczyk M; Butenas S; Undas A
Eur J Clin Invest; 2023 Sep; 53(9):e14007. PubMed ID: 37042848
[TBL] [Abstract][Full Text] [Related]
28. Clinical outcomes and plasma clot permeability and lysability in patients with venous thromboembolism on rivaroxaban: a cohort study.
Frączek P; Krzysztofik M; Stanisz A; Undas A
Pol Arch Intern Med; 2019 Jun; 129(6):377-385. PubMed ID: 31063157
[TBL] [Abstract][Full Text] [Related]
29. Prolonged duration of type 2 diabetes is associated with increased thrombin generation, prothrombotic fibrin clot phenotype and impaired fibrinolysis.
Konieczynska M; Fil K; Bazanek M; Undas A
Thromb Haemost; 2014 Apr; 111(4):685-93. PubMed ID: 24306139
[TBL] [Abstract][Full Text] [Related]
30. Prothrombotic alterations in plasma fibrin clot properties in thyroid disorders and their post-treatment modifications.
Mazur P; Sokołowski G; Hubalewska-Dydejczyk A; Płaczkiewicz-Jankowska E; Undas A
Thromb Res; 2014 Aug; 134(2):510-7. PubMed ID: 24962680
[TBL] [Abstract][Full Text] [Related]
31. Does cell-free DNA promote coagulation and inhibit fibrinolysis in patients with unprovoked venous thromboembolism?
Medeiros SK; Emery B; Bhagirath V; Parpia S; Dwivedi DJ; Dwivedi NJ; Kearon C; Liaw PC
Thromb Res; 2020 Feb; 186():13-19. PubMed ID: 31838139
[TBL] [Abstract][Full Text] [Related]
32. Altered fibrin clot properties are associated with the progression of chronic kidney disease in atrial fibrillation.
Heleniak Z; Matusik PT; Undas A
Thromb Res; 2024 Apr; 236():14-21. PubMed ID: 38387299
[TBL] [Abstract][Full Text] [Related]
33. Markers of NET formation and stroke risk in patients with atrial fibrillation: association with a prothrombotic state.
Mołek P; Ząbczyk M; Malinowski KP; Natorska J; Undas A
Thromb Res; 2022 May; 213():1-7. PubMed ID: 35276507
[TBL] [Abstract][Full Text] [Related]
34. Altered fibrin clot structure/function in patients with antiphospholipid syndrome: association with thrombotic manifestation.
Celińska-Lowenhoff M; Iwaniec T; Padjas A; Musiał J; Undas A
Thromb Haemost; 2014 Aug; 112(2):287-96. PubMed ID: 24652596
[TBL] [Abstract][Full Text] [Related]
35. Vitamin K antagonists favourably modulate fibrin clot properties in patients with atrial fibrillation as early as after 3days of treatment: Relation to coagulation factors and thrombin generation.
Ząbczyk M; Majewski J; Karkowski G; Malinowski KP; Undas A
Thromb Res; 2015 Oct; 136(4):832-8. PubMed ID: 26319777
[TBL] [Abstract][Full Text] [Related]
36. Reduced plasma fibrin clot permeability is associated with recurrent thromboembolic events in patients with antiphospholipid syndrome.
Celinska-Löwenhoff M; Zabczyk M; Iwaniec T; Plens K; Musial J; Undas A
Rheumatology (Oxford); 2018 Aug; 57(8):1340-1349. PubMed ID: 29672756
[TBL] [Abstract][Full Text] [Related]
37. Reduced plasma fibrin clot permeability and susceptibility to fibrinolysis are associated with increased intima-media thickness in patients with primary antiphospholipid syndrome.
Asztabski M; Wypasek E; Ząbczyk M; Undas A
Thromb Res; 2014 Nov; 134(5):945-51. PubMed ID: 25194881
[TBL] [Abstract][Full Text] [Related]
38. Accelerated fibrin clot degradation is associated with arterial thromboembolism in patients following venous thrombosis: a cohort study.
Mrozinska S; Wypasek E; Broniatowska E; Undas A
Sci Rep; 2021 Oct; 11(1):21003. PubMed ID: 34702844
[TBL] [Abstract][Full Text] [Related]
39. Effect of rosuvastatin on risk markers for venous thromboembolism in cancer.
Ades S; Douce D; Holmes CE; Cory S; Prior S; Butenas S; Callas P; Cushman M
J Thromb Haemost; 2018 Jun; 16(6):1099-1106. PubMed ID: 29575637
[TBL] [Abstract][Full Text] [Related]
40. Unfavorably Altered Fibrin Clot Properties in Patients with Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss Syndrome): Association with Thrombin Generation and Eosinophilia.
Mastalerz L; Celińska-Lӧwenhoff M; Krawiec P; Batko B; Tłustochowicz W; Undas A
PLoS One; 2015; 10(11):e0142167. PubMed ID: 26540111
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
